Form 4: Foghorn Therapeutics CSO Granted 300,000 Stock Options

Foghorn Therapeutics' Chief Scientific Officer, Steven F. Bellon, was granted 300,000 stock options at an exercise price of $5.71.

Summary

• Steven F. Bellon, Chief Scientific Officer of Foghorn Therapeutics Inc. (FHTX), was granted 300,000 stock options.
• The transaction date for this grant was January 30, 2026.
• The exercise price for these options is $5.71 per share.
• The options will vest as to 25% of the underlying shares on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
• The expiration date for these stock options is January 29, 2036.
• Following this transaction, Steven F. Bellon directly beneficially owns 300,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation action rather than a direct indicator of company performance or strategic shift.

Positives

• The grant of stock options aligns the Chief Scientific Officer's financial interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a significant window for potential value realization.

Future Outlook

The filing details a stock option grant with a future vesting schedule, indicating a long-term incentive structure for the Chief Scientific Officer. The vesting schedule extends through future calendar quarters, with the first significant vesting event on January 30, 2027.

Industry Context

Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, including for companies like Foghorn Therapeutics. StockSavvy.ai notes that these grants are designed to attract and retain key talent, aligning executive incentives with long-term shareholder value creation, particularly in sectors with long development cycles and high R&D costs.

Comparison to Industry Standards

• The grant of 300,000 stock options to a Chief Scientific Officer is a common practice for incentivizing key executives in growth-oriented biotech firms, comparable to compensation structures seen at peers like CRISPR Therapeutics or Editas Medicine, where equity forms a significant portion of total compensation.
• The 10-year expiration period and multi-year vesting schedule are typical for long-term incentive plans in the life sciences sector, aiming to retain talent and reward sustained performance over several years, similar to programs at companies developing novel therapies.

Corporate Governance

Related Party Transactions

• The grant of 300,000 stock options to Steven F. Bellon, the Chief Scientific Officer, constitutes a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased long-term value creation due to aligned executive incentives.
• Employees: May signal the company's commitment to retaining key talent through equity compensation.

Next Steps

• The stock options will begin vesting on January 30, 2027, with 25% of the underlying shares.
• Subsequent vesting will occur at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a company executive, which is a standard component of compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it reflects a neutral event in the context of an investment decision.

Keywords

Foghorn Therapeutics, FHTX, Stock Option Grant, Insider Transaction, Chief Scientific Officer, Executive Compensation, Form 4, Equity Compensation